GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InhaleRx Ltd (ASX:IRX) » Definitions » Short Percentage of Float

InhaleRx (ASX:IRX) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of InhaleRx's Short Percentage of Float

For the Medical Devices subindustry, InhaleRx's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InhaleRx's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InhaleRx's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where InhaleRx's Short Percentage of Float falls into.


;
;

InhaleRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InhaleRx Ltd (ASX:IRX) » Definitions » Short Percentage of Float
Comparable Companies
ASX:UCM ASX:ADRDA ASX:CBL ASX:AT1 ASX:HMD ASX:OSL ASX:UBI ASX:LDX ASX:CDX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE ZBH
Traded in Other Exchanges
N/A
Address
C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Website
https://www.inhalerx.com.au
InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines